)
Telix Pharmaceuticals (TLX) investor relations material
Telix Pharmaceuticals Bell Potter Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Commercial platform and outlook
Three FDA-approved precision medicine products serve prostate and brain cancer; commercial sales span 22 countries, supported by 45 manufacturing sites globally.
2026 revenue expected just under US$1 billion, with guidance projected at the top end; precision medicine revenue is expected to grow more than 25% YoY.
Radiopharma growth drivers targeted for 2027 include Illuccix and Gozellix, new products and indications, expansion into China and Japan, Telix Manufacturing Solutions revenue, and ITM assets.
ITM acquisition is intended to secure lutetium supply and add complementary pipeline assets; settlement is due early in 2027.
BiPASS prostate study
Phase III BiPASS compares gallium PSMA PET plus MRI with MRI alone for detecting clinically significant prostate cancer; 350 patients enrolled at U.S. and Australian sites, with enrollment completed in June.
The trial builds on PRIMARY2 findings that PSMA PET could help roughly half of patients avoid biopsy without missing clinically significant cancer; its FDA-negotiated design is intended to generate submission-ready data.
Six-month follow-up puts study data due around Q1 2027; a new drug application is planned for Q2 2027, following granted fast-track designation.
Starting in 2027, PSMA PET plus MRI is expected to support biopsy avoidance for suitable patients and more targeted biopsies for others.
Pixclara and brain imaging
FDA approved Pixclara, a FET PET imaging agent, in September for assessing suspected recurrent glioma after initial treatment; commercial use has begun.
Pixclara currently uses a not-otherwise-classified reimbursement code; a temporary pass-through code is expected in Q1 2027, when broader commercial scale-up is anticipated.
A Phase III trial is about to start to pursue a brain-metastases indication, a market described as about 10 times the size of primary brain cancer.
- A broad radiopharma pipeline and supply expansion set up a major 2027 catalyst year.TLX
UBS Global Biopharma Conference 2026 - FY26 guidance and ITM integration underpin a 2027 growth step-up.TLX
CMD 2026 - Revenue rose 214%, turning FY2023 profitable as cash flow funded pipeline growth.TLX
H2 2023 - Revenue rose 19% YoY as Pixclara approval and the ITM merger advanced growth plans.TLX
Q3 2026 TU - Late-stage pipeline, global expansion, and strategic deals drive radiopharma leadership.TLX
R&D Day 2026 - US$1.65B merger creates a global radiopharma leader with EBITDA positivity targeted by 2027.TLX
M&A announcement - Imaging-driven growth funds late-stage trials in urology and neuro-oncology, with major data ahead.TLX
H.C. Wainwright 28th Annual Global Investment Conference - FDA approval, pipeline expansion, and integrated distribution drive radiopharma leadership.TLX
Morgan Stanley 24th Annual Global Healthcare Conference - Revenue up 22% to $477.3M, net profit $38.3M, margin and pipeline gains drive strong outlook.TLX
H1 2026
)
)
)
)
)
)
)
)